Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Further trials should conduct better randomization and blinding procedures, recruit more participants, and provide adequate reporting
Additional at-risk groups include: Vegans and strict vegetarians , who may have low dietary B12 intake People with autoimmune conditions , including pernicious anaemia or type 1 diabetes Individuals with gastrointestinal conditions such as Crohn's disease or coeliac disease, which impair nutrient absorption People who have undergone bariatric surgery , which can significantly reduce B12 absorption Long-term users of proton pump inhibitors (PPIs) or H2-receptor antagonists , which reduce gastric acid and impair B12 release from food Those with a family history of either pernicious anaemia or diabetes For these groups, simultaneous monitoring of B12 status and glycaemic markers is particularly important to avoid diagnostic errors
Nicotinamide N-methyltransferase inhibitors: A patent review
Dosing Protocol A suggested daily approach based on preclinical reference doses for this NNMT inhibitor
